Clinical trial NCT00005332 - References

Hypertension — Antihypertensive Drug/Gene Interactions and CV Events

Citation(s)

•   Au DH, Lemaitre RN, Curtis JR, Smith NL, Psaty BM
  The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists. Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):827-30.
•   Bis JC, Smith NL, Psaty BM, Heckbert SR, Edwards KL, Lemaitre RN, Lumley T, Rosendaal FR
  Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. Am J Hypertens. 2003 Dec;16(12):1011-7.
•   Glazer NL, Smith NL, Heckbert SR, Doggen CJ, Lemaitre RN, Psaty BM
  Risk of myocardial infarction attributable to elevated levels of total cholesterol among hypertensives. Am J Hypertens. 2005 Jun;18(6):759-66.
•   Green BB, Kaplan RC, Psaty BM
  How do minor changes in the definition of blood pressure control affect the reported success of hypertension treatment? Am J Manag Care. 2003 Mar;9(3):219-24.
•   Heckbert SR, Weiss NS, Koepsell TD, Lemaitre RN, Smith NL, Siscovick DS, Lin D, Psaty BM
  Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. Arch Intern Med. 1997 Jun 23;157(12):1330-6.
•   Kaplan RC, Heckbert SR, Furberg CD, Psaty BM
  Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol. 2002 Jul;55(7):654-64.
•   Kaplan RC, Heckbert SR, Koepsell TD, Rosendaal FR, Psaty BM
  Use of calcium channel blockers and risk of hospitalized gastrointestinal tract bleeding. Arch Intern Med. 2000 Jun 26;160(12):1849-55.
•   Kaplan RC, Psaty BM, Heckbert SR, Smith NL, Lemaitre RN
  Blood pressure level and incidence of myocardial infarction among patients treated for hypertension. Am J Public Health. 1999 Sep;89(9):1414-7.
•   Kaplan RC, Psaty BM, Kriesel D, Heckbert SR, Smith NL, Gillett C, Golston AG
  Replacing short-acting nifedipine with alternative medications at a large health maintenance organization. Am J Hypertens. 1998 Apr;11(4 Pt 1):471-7.
•   Klungel OH, Heckbert SR, Longstreth WT Jr, Furberg CD, Kaplan RC, Smith NL, Lemaitre RN, Leufkens HG, de Boer A, Psaty BM
  Antihypertensive drug therapies and the risk of ischemic stroke. Arch Intern Med. 2001 Jan 8;161(1):37-43.
•   Klungel OH, Kaplan RC, Heckbert SR, Smith NL, Lemaitre RN, Longstreth WT Jr, Leufkens HG, de Boer A, Psaty BM
  Control of blood pressure and risk of stroke among pharmacologically treated hypertensive patients. Stroke. 2000 Feb;31(2):420-4.
•   Lahad A, Heckbert SR, Koepsell TD, Psaty BM, Patrick DL
  Hostility, aggression and the risk of nonfatal myocardial infarction in postmenopausal women. J Psychosom Res. 1997 Aug;43(2):183-95.
•   Lahad A, Heckbert SR, Patrick DL, Psaty BM
  Hostility, aggression and the association with hypertension in post-menopausal women. J Hum Hypertens. 1996 Sep;10 Suppl 3:S115-21.
•   Lemaitre RN, Heckbert SR, Psaty BM, Siscovick DS
  Leisure-time physical activity and the risk of nonfatal myocardial infarction in postmenopausal women. Arch Intern Med. 1995 Nov 27;155(21):2302-8.
•   Psaty BM, Boineau R, Kuller LH, Luepker RV
  The potential costs of upcoding for heart failure in the United States. Am J Cardiol. 1999 Jul 1;84(1):108-9, A9.
•   Psaty BM, Furberg CD, Pahor M, Alderman M, Kuller LH
  National guidelines, clinical trials, and quality of evidence. Arch Intern Med. 2000 Sep 25;160(17):2577-80.
•   Psaty BM, Furberg CD
  Clinical implications of the World Health Organization-International Society of Hypertension statement on calcium antagonists. J Hypertens. 1997 Nov;15(11):1197-200.
•   Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, Siscovick DS, Wagner EH
  The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med. 1994 Jun 27;154(12):1333-9.
•   Psaty BM, Heckbert SR, Atkins D, Siscovick DS, Koepsell TD, Wahl PW, Longstreth WT Jr, Weiss NS, Wagner EH, Prentice R, et al
  A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women. Arch Intern Med. 1993 Jun 28;153(12):1421-7. Review.
•   Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, et al
  The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995 Aug 23-30;274(8):620-5.
•   Psaty BM, Koepsell TD, Lin D, Weiss NS, Siscovick DS, Rosendaal FR, Pahor M, Furberg CD
  Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc. 1999 Jun;47(6):749-54.
•   Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS
  Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003 May 21;289(19):2534-44.
•   Psaty BM, Rennie D
  Stopping medical research to save money: a broken pact with researchers and patients. JAMA. 2003 Apr 23-30;289(16):2128-31.
•   Psaty BM, Siscovick DS, Weiss NS, Koepsell TD, Rosendaal FR, Lin D, Heckbert SR, Wagner EH, Furberg CD
  Hypertension and outcomes research. From clinical trials to clinical epidemiology. Am J Hypertens. 1996 Feb;9(2):178-83. Review.
•   Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP, Siscovick DS, Bis J, Lumley T, Longstreth WT Jr, Rosendaal FR
  Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA. 2002 Apr 3;287(13):1680-9.
•   Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD
  Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA. 1997 Mar 5;277(9):739-45.
•   Psaty BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal FR, Smith NL, Heckbert SR, Kaplan RC, Lin D, Fleming TR, Wagner EH
  Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA. 1999 Aug 25;282(8):786-90.
•   Rea TD, Heckbert SR, Kaplan RC, Smith NL, Lemaitre RN, Psaty BM
  Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med. 2002 Sep 17;137(6):494-500.
•   Rhoads CS, Psaty BM, Olson JL, Furberg CD
  Medications and cardiovascular health in older adults: room for improvement in prevention and treatment. Am J Geriatr Cardiol. 2004 May-Jun;13(3):161-7. Review.
•   Schellenbaum GD, Smith NL, Heckbert SR, Lumley T, Rea TD, Furberg CD, Lyles MF, Psaty BM
  Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension. J Am Geriatr Soc. 2005 Nov;53(11):1996-2000.
•   Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, Larson EB, Rosendaal FR, Psaty BM
  Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA. 2004 Oct 6;292(13):1581-7.
•   Smith NL, Lemaitre RN, Heckbert SR, Kaplan RC, Tirschwell DL, Longstreth WT, Psaty BM
  Serum potassium and stroke risk among treated hypertensive adults. Am J Hypertens. 2003 Oct;16(10):806-13.
•   Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM
  Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology. 2004 Nov 23;63(10):1868-75.

Details for clinical trial NCT00005332